Apogee Therapeutics initiated with an Outperform at TD Cowen

TD Cowen initiated coverage of Apogee Therapeutics with an Outperform rating and no price target. Apogee is “a next-gen I&I company” whose lead programs APG777 and APG808 have high odds of success as each utilize the same epitope as lebrikizumab and Dupixent, respectively, the analyst tells investors. The firm sees potential for Apogee to generate $10B of sales, the analyst noted.